2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
CNS
1
Conditions
Sleep Initiation and Maintenance Disorders
30
Neoplasms
22
Breast Neoplasms
20
Anxiety Disorders
13
Depression
12
Prostatic Neoplasms
8
Fatigue
8
Lung Neoplasms
5
Motor Activity
4
Lymphoma
4
Weight Loss
3
Uterine Cervical Neoplasms
3
Ovarian Neoplasms
3
Melanoma
3
Colorectal Neoplasms
3
Chronic Pain
3
Smoking Cessation
2
Sleep Wake Disorders
2
Pain
2
Overweight
2
Obesity
2
Nervous System Diseases
2
Multiple Myeloma
2
Lymphoma, Follicular
2
Glioma
2
Glioblastoma
2
Cognitive Dysfunction
2
Carcinoma, Non-Small-Cell Lung
2
Weight Gain
1
Uterine Neoplasms
1
Interventions
Temozolomide
74
Radiotherapy
34
Carboplatin
21
Bevacizumab
18
Magnetic Resonance Spectroscopy
17
Irinotecan
16
Carmustine
16
Vincristine
14
Surgical Procedures, Operative
13
Filgrastim
13
Procarbazine
10
Erlotinib Hydrochloride
8
Cyclophosphamide
8
Peripheral Blood Stem Cell Transplantation
7
O(6)-benzylguanine
7
Lomustine
7
Etoposide
7
sargramostim
6
Imatinib Mesylate
6
Flucytosine
6
Cisplatin
6
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
6
temsirolimus
5
Vorinostat
5
Thiotepa
5
Radiotherapy, Intensity-Modulated
5
Radiation
5
Immunohistochemistry
5
Biopsy
5
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Oligodendroglioma
×
Cognitive Behavioral Therapy
×
Clear all
NCT06439420
2025-10-01
CBT-I in PBT
Virginia Commonwealth University
Phase 2
Completed
70 enrolled